Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials (vol 399, pg 2113, 2022)

被引：0
|
作者：
Danese, S.
Vermeire, S.
Zhou, W.
机构：
来源：
LANCET | 2022年 / 400卷 / 10357期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：996 / 996
页数：1
相关论文
共 50 条
  • [1] Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
    Danese, Silvio
    Vermeire, Severine
    Zhou, Wen
    Pangan, Aileen L.
    Siffledeen, Jesse
    Greenbloom, Susan
    Hebuterne, Xavier
    D'Haens, Geert
    Nakase, Hiroshi
    Panes, Julian
    Higgins, Peter D. R.
    Juillerat, Pascal
    Lindsay, James O.
    Loftus, Edward V., Jr.
    Sandborn, William J.
    Reinisch, Walter
    Chen, Min-Hu
    Gonzalez, Yuri Sanchez
    Huang, Bidan
    Xie, Wangang
    Liu, John
    Weinreich, Michael A.
    Panaccione, Remo
    [J]. LANCET, 2022, 399 (10341): : 2113 - 2128
  • [2] Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
    Vermeire, Severine
    Danese, Silvio
    Zhou, Wen
    Ilo, Dapo
    Klaff, Justin
    Levy, Gweneth
    Yao, Xuan
    Chen, Su
    Gonzalez, Yuri Sanchez
    Hebuterne, Xavier
    Lindsay, James
    Higgins, Peter D. R.
    Cao, Qian
    Nakase, Hiroshi
    Colombel, Jean-Frederic
    Loftus, Edward V., Jr.
    Panaccione, Remo
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11): : 976 - 989
  • [3] Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study
    Vermeire, Severine
    Lakatos, Peter L.
    Ritter, Timothy
    Hanauer, Stephen
    Bressler, Brian
    Khanna, Reena
    Isaacs, Kim
    Shah, Saumin
    Kadva, Alysha
    Tyrrell, Helen
    Oh, Young S.
    Tole, Swati
    Chai, Akiko
    Pulley, Jennifer
    Eden, Christopher
    Zhang, Wenhui
    Feagan, Brian G.
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (01): : 28 - 37
  • [4] Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials (vol 7, pg 17, 2022)
    Rubin, D. T.
    Dotan, I
    DuVall, A.
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (04): : E8 - E8
  • [5] Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials
    Friedrich, S.
    Chua, L.
    Zhang, X. C.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 646 - 646
  • [6] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM RANDOMISED PHASE 2 AND PHASE 3 INDUCTION AND MAINTENANCE TRIALS
    Friedrich, Stuart
    Chua, Laiyi
    Zhang, Xin
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S1217 - S1218
  • [7] Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
    Ferrante, Marc
    Panaccione, Remo
    Baert, Filip
    Bossuyt, Peter
    Colombel, Jean-Frederic
    Danese, Silvio
    Dubinsky, Marla
    Feagan, Brian G.
    Hisamatsu, Tadakazu
    Lim, Allen
    Lindsay, James O.
    Loftus, Edward V., Jr.
    Panes, Julian
    Peyrin-Biroulet, Laurent
    Ran, Zhihua
    Rubin, David T.
    Sandborn, William J.
    Schreiber, Stefan
    Neimark, Ezequiel
    Song, Alexandra
    Kligys, Kristina
    Pang, Yinuo
    Pivorunas, Valerie
    Berg, Sofie
    Duan, W. Rachel
    Huang, Bidan
    Kalabic, Jasmina
    Liao, Xiaomei
    Robinson, Anne
    Wallace, Kori
    D'Haens, Geert
    [J]. LANCET, 2022, 399 (10340): : 2031 - 2046
  • [8] Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE Study
    Danese, Silvio
    Vermeire, Severine
    Zhou, Wen
    Pangan, Aileen
    Siffledeen, Jesse
    Hebuterne, Xavier
    Nakase, Hiroshi
    Chen, Minhu
    Higgins, Peter
    Sanchez-Gonzalez, Yuri
    Huang, Bidan
    Xian, Wangang
    Liu, Jianzhong
    Weinreich, Michael
    Panaccione, Remo
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S312 - S313
  • [9] Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study
    Danese, S.
    Vermeire, S.
    Zhou, W.
    Pangan, A.
    Siffledeen, J.
    Hebuterne, X.
    Nakase, H.
    Higgins, P.
    Chen, M. H.
    Sanchez-Gonzalez, Y.
    Huang, B.
    Xie, W.
    Liu, J.
    Weinreich, M.
    Pannaccione, R.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S022 - S024
  • [10] Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
    Vermeire, S.
    Danese, S.
    Zhou, W.
    Pangan, A.
    Greenbloom, S.
    D'Haens, G.
    Panes, J.
    Juillerat, P.
    Lindsay, J. O.
    Loftus, E. V., Jr.
    Sandborn, W. J.
    Reinisch, W.
    Gonzalez, Y. Sanchez
    Huang, B.
    Xie, W.
    Liu, J.
    Weinreich, M. A.
    Panaccione, R.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S021 - S022
12345